SK283072B6 - Perorálny prípravok na prevenciu a liečbu parvovirózy psov a spôsob jeho výroby - Google Patents
Perorálny prípravok na prevenciu a liečbu parvovirózy psov a spôsob jeho výroby Download PDFInfo
- Publication number
- SK283072B6 SK283072B6 SK1475-98A SK147598A SK283072B6 SK 283072 B6 SK283072 B6 SK 283072B6 SK 147598 A SK147598 A SK 147598A SK 283072 B6 SK283072 B6 SK 283072B6
- Authority
- SK
- Slovakia
- Prior art keywords
- canine
- composition
- immunized
- colostrum
- amount
- Prior art date
Links
- 241000282465 Canis Species 0.000 title claims abstract description 16
- 230000003449 preventive effect Effects 0.000 title abstract description 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 235000021277 colostrum Nutrition 0.000 claims abstract description 19
- 210000003022 colostrum Anatomy 0.000 claims abstract description 19
- 241000701931 Canine parvovirus Species 0.000 claims abstract description 11
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 11
- 241000283690 Bos taurus Species 0.000 claims abstract description 10
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 239000000427 antigen Substances 0.000 claims abstract description 6
- 102000036639 antigens Human genes 0.000 claims abstract description 6
- 108091007433 antigens Proteins 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 14
- 239000000047 product Substances 0.000 abstract description 6
- 238000002649 immunization Methods 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 239000013067 intermediate product Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 241000125945 Protoparvovirus Species 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 8
- 208000008071 Parvoviridae Infections Diseases 0.000 description 7
- 206010057343 Parvovirus infection Diseases 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010003504 Aspiration Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000020992 canned meat Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- LQZPJQKYAOYUJS-UHFFFAOYSA-N n,n-diethyl-2-phenothiazin-10-ylethanamine;hydron;chloride Chemical compound Cl.C1=CC=C2N(CCN(CC)CC)C3=CC=CC=C3SC2=C1 LQZPJQKYAOYUJS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000005181 root of the tongue Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ19973489A CZ287956B6 (cs) | 1997-11-04 | 1997-11-04 | Perorální přípravek k prevenci a léčbě parvovirózy psů |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK147598A3 SK147598A3 (en) | 1999-06-11 |
| SK283072B6 true SK283072B6 (sk) | 2003-02-04 |
Family
ID=5466828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1475-98A SK283072B6 (sk) | 1997-11-04 | 1998-10-28 | Perorálny prípravok na prevenciu a liečbu parvovirózy psov a spôsob jeho výroby |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0914831B1 (cs) |
| AT (1) | ATE237355T1 (cs) |
| CZ (1) | CZ287956B6 (cs) |
| DE (1) | DE69813448T2 (cs) |
| PL (1) | PL191018B1 (cs) |
| SK (1) | SK283072B6 (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ287989B6 (cs) * | 1998-03-20 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat |
| WO2003041512A1 (en) * | 2001-11-12 | 2003-05-22 | Mars, Incorporated | Foodstuff |
| JP2004352693A (ja) * | 2003-05-30 | 2004-12-16 | Gen Corp:Kk | 抗パルボウイルス感染症組成物 |
| US6866868B1 (en) * | 2003-09-15 | 2005-03-15 | 4Life Research, Lc | Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions |
| US20070207187A1 (en) * | 2004-09-29 | 2007-09-06 | Mizuo Yajima | Functional Composition Or Food Comprising Whey Protein, Antibody Derived From Milk Or Antibody |
| US10471100B2 (en) * | 2006-09-29 | 2019-11-12 | 4Life Patents, Llc | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| US12059446B1 (en) * | 2005-05-20 | 2024-08-13 | 4Life Patents, Llc | Compositions and methods for supporting metabolic and endocrine system function |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| CN105012950A (zh) | 2010-11-23 | 2015-11-04 | 潘瑟里克公司 | 用于在广谱、未分化或混合临床应用中治疗的组合物和方法 |
| DE102011006535A1 (de) | 2011-03-31 | 2012-10-04 | Lr Health & Beauty Systems Gmbh | Ergänzungsfuttermittel für Tiere |
| WO2020176637A1 (en) | 2019-02-26 | 2020-09-03 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
| EP4004035A4 (en) | 2019-07-30 | 2023-06-28 | Kindred Biosciences, Inc. | Parvovirus antibodies for veterinary use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748018A (en) * | 1984-02-07 | 1988-05-31 | Stolle Research & Development Corp. | Method of passive immunization of mammals using avian antibody |
| ES2026826A6 (es) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados. |
| WO1994021284A1 (en) * | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
| US5814510A (en) * | 1994-11-08 | 1998-09-29 | Cornell Research Foundation, Inc. | Attenuated canine parvovirus vaccine |
| JPH08259462A (ja) * | 1994-12-05 | 1996-10-08 | Adtec Kk | 抗パルボウイルス感染症組成物 |
-
1997
- 1997-11-04 CZ CZ19973489A patent/CZ287956B6/cs not_active IP Right Cessation
-
1998
- 1998-10-22 AT AT98308655T patent/ATE237355T1/de not_active IP Right Cessation
- 1998-10-22 EP EP98308655A patent/EP0914831B1/en not_active Expired - Lifetime
- 1998-10-22 DE DE69813448T patent/DE69813448T2/de not_active Expired - Lifetime
- 1998-10-28 SK SK1475-98A patent/SK283072B6/sk not_active IP Right Cessation
- 1998-11-03 PL PL329570A patent/PL191018B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69813448T2 (de) | 2004-03-25 |
| EP0914831A2 (en) | 1999-05-12 |
| SK147598A3 (en) | 1999-06-11 |
| EP0914831A3 (en) | 1999-06-30 |
| PL329570A1 (en) | 1999-05-10 |
| DE69813448D1 (de) | 2003-05-22 |
| CZ348997A3 (cs) | 2000-01-12 |
| PL191018B1 (pl) | 2006-03-31 |
| EP0914831B1 (en) | 2003-04-16 |
| ATE237355T1 (de) | 2003-05-15 |
| CZ287956B6 (cs) | 2001-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Uruakpa et al. | Colostrum and its benefits: a review | |
| EP0706400A1 (en) | Therapeutic formulation and method | |
| CZ287989B6 (cs) | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat | |
| US20250222101A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| SK283072B6 (sk) | Perorálny prípravok na prevenciu a liečbu parvovirózy psov a spôsob jeho výroby | |
| CN112996808A (zh) | 用于治疗动物急性腹泻和肠道感染的组合物和方法 | |
| CN108371247A (zh) | 一种提高仔猪存活率的复合益生菌 | |
| CN102696887B (zh) | 一种具有营养保健促生长功能的饲料活性蛋粉及其生产方法 | |
| JP4073922B2 (ja) | ビフィズス菌増殖促進成分を含有する飼料組成物とその使用方法 | |
| EP0930316B1 (en) | Oral product for the prevention and treatment of infectious gastroenteritides in calves | |
| JPH10265393A (ja) | 豚流行性下痢の予防治療剤 | |
| Moore et al. | Effect of colostrum on the vitamin A and carotene content of blood plasma of new-born calves | |
| RU2833809C1 (ru) | Способ непрямой регуляции иммунологических процессов у телят в период новорождённости для снижения риска развития желудочно-кишечных заболеваний | |
| US6296879B1 (en) | Ruminal fluid inoculation of calves | |
| JP2004352693A (ja) | 抗パルボウイルス感染症組成物 | |
| WO1997035490A1 (en) | Colostrum food supplement | |
| JPH04211613A (ja) | 経口日和見感染症防止治療用組成物 | |
| Muscato et al. | Ruminal fluid inoculation of calves | |
| Kumaresan et al. | Strategizing managemental practices for dairy calves | |
| BG3644U1 (bg) | Биологично-активен полибактериален продукт за имуностимулация при животни | |
| WO2002067692A1 (en) | Ruminal fluid inoculation of calves | |
| BG1141U1 (bg) | Полибактериален комплекс за имунопрофилактика и имунотерапия при млекопитаещи животни и лекарственаформа, която го съдържа | |
| AU6278794A (en) | Therapeutic formulation and method | |
| CS201369B1 (cs) | Biopreparét na ochranu mléáat hospodářských zvířat proti střevním infekcím |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20151028 |